Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor

Patent metadata

Field	Value
Publication number	US-10017524-B2
Application number	US-201715660364-A
Country	US
Kind code	B2
Filing date	Jul 26, 2017
Priority date	Jul 30, 2012
Publication date	Jul 10, 2018
Grant date	Jul 10, 2018

Abstract

The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition. One or more embodiments disclose a compound expressed by the following general formula (I) or (II) or a pharmaceutically acceptable salt of the compound:

First claim

The invention claimed is:

1. A compound expressed by the following formula (II) or a prodrug of the compound or a pharmaceutically acceptable salt of the compound:

wherein, in the formula (II),
X and Y each independently represent S or NH,
R 5 represents

wherein Z and atoms marked with a and b form a ring selected from the group consisting of one benzene ring, one heteroaromatic ring, an aromatic ring in which one or more benzene rings are condensed, a heteroaromatic ring in which one or more heteroaromatic rings are condensed, a mixed condensed polycyclic ring in which one or more benzene rings are condensed with one or more heteroaromatic rings, and a cyclic aliphatic, and the ring may have at least one substituent that is a hydrogen atom, a halogen atom, or a C 1-6 alkyl group, and
R 6 represents a hydrogen atom, a halogen atom, or a C 1-6 alkyl group,
with the proviso that the compound is not:

2. The compound according to claim 1 expressed by

or a prodrug of the compound or a pharmaceutically acceptable salt of the compound.

3. A pharmaceutical composition containing the compound according to claim 1 or the pharmaceutically acceptable salt of the compound according to claim 1 as an active ingredient.

4. A method for treating Down's syndrome, brain cancer, lung cancer, or breast cancer, said method comprising:
administering a compound expressed by the following formula (II) or a prodrug of the compound or a pharmaceutically acceptable salt of the compound to a subject:

wherein, in the formula (II),
X and Y each independently represent S or NH,
R 5 represents

wherein Z and atoms marked with a and b form a ring selected from the group consisting of one benzene ring, one heteroaromatic ring, an aromatic ring in which one or more benzene rings are condensed, a heteroaromatic ring in which one or more heteroaromatic rings are condensed, a mixed condensed polycyclic ring in which one or more benzene rings are condensed with one or more heteroaromatic rings, and a cyclic aliphatic, and the ring may have at least one substituent that is a hydrogen atom, a halogen atom, or a C 1-6 alkyl group, and
R 6 represents a hydrogen atom, a halogen atom, or a C 1-6 alkyl group,
with the proviso that the compound is not:

5. The method for treating Down's syndrome, brain cancer, lung cancer, or breast cancer, said method comprising:
administering a compound expressed by

or a prodrug of the compound or a pharmaceutically acceptable salt of the compound to a subject.

6. The method of claim 5 , which comprises administering a compound of the formula

to a subject.

7. The compound of claim 2 , of the formula

8. A pharmaceutical composition containing the compound according to claim 2 or the pharmaceutically acceptable salt of the compound according to claim 2 as an active ingredient.

9. A pharmaceutical composition containing the compound according to claim 7 or the pharmaceutically acceptable salt of the compound according to claim 7 as an active ingredient.

Assignees

• Univ Kyoto
• Univ Nat Corp Tokyo Medical & Dental
• Kinopharma Inc

Inventors

• Hagiwara Masatoshi
• Onogi Hiroshi
• Kii Isao
• Hosoya Takamitsu
• SUMIDA Yuto

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07D513/04 Primary

  Ortho-condensed systems · CPC title